Episode 147: GU Podcast (2020): Chemo-ablation Of Upper-Tract Urothelial Carcinoma

At the conclusion of this activity, participants will be able to:
1. Identify new technologies for the treatment of urothelial carcinoma and analyze the risks and benefits of treatment.
2. Facilitate discussions with patients and caregivers regarding of urothelial carcinoma treatment options.

This educational series is supported by independent educational grants from:

  • Astellas
  • AstraZeneca
  • Bristol Myers Squibb
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Merck
  • Pfizer, Inc
  • Sanofi Genzyme
  • UroGen Pharma, Inc.

CME Available: auau.auanet.org/node/29841